What this is
- How it works
- How it works isn't classified yet
- Main trialPhase 2
- “This is a Phase 2 dose-finding study in adult participants with symptomatic HFpEF.”In the company’s words, NCT06793371 on ClinicalTrials.gov
- Other names
- ulacamten
Other drugs for Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF)
- Balcinrenone/ dapagliflozinAstraZeneca · Phase 3
- DapagliflozinAstraZeneca · Phase 3
- HiCM-188HELP Therapeutics Co., Ltd. · Phase 3
- Omecamtiv MecarbilCytokinetics · Phase 3
- InclisiranNovartis · Phase 3
- EmpagliflozinBoehringer Ingelheim · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | Sep 2026 | AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF | |
| Phase 1Completed | 20 Nov 2024 | A Single and Multiple Ascending Dose Study of CK-4021586 in Healthy Adult Participants |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026